Sanofi
Sanofi Invests €300M in Orano Med to Advance Radioligand Therapies
The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.
Vir Biotechnology Completes Licensing Deal With Sanofi for Three T-Cell Engager Programs
Vir gained exclusive worldwide rights to HER2-targeted, PSMA-targeted, and EGFR-targeted T-cell engager assets.
MeiraGTx Gets $30M Equity Investment From Sanofi
The investment is part of MeiraGTx's sale of ordinary shares worth about $50 million, which will help the company fund operations through early 2026.
Genzyme Sues Sarepta for Alleged Patent Infringement on Muscular Dystrophy Treatment Elevidys
Genzyme has accused Sarepta of infringing two patents related to methods for preventing AAV aggregation and asked for unspecified damages.
Sanofi Invests $40M in Vigil Neuroscience, Gets Exclusive License Option to TREM2 Program
Sanofi gains the right of first negotiation to license agents in this program, including a drug being tested in a genomically defined Alzheimer's population.